Loading
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Previous close
$2.46
+$0.12 · +5.13%
Regular session · ET · Market data may be delayed.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Day range
Current $2.46
52-week range
Current $2.46
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
62
Bullish
Risk
47
Elevated Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
Day range
Current $2.46
52-week range
Current $2.46
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.25M USD | 566K USD | 392K USD | 1.5M USD | 208.38M USD |
| Cost of goods sold | 300K USD | — | — | — | — |
| Gross profit | 6.95M USD | 566K USD | 392K USD | 1.5M USD | 208.38M USD |
| Research and development | 25.58M USD | 36.77M USD | 28.59M USD | 24.62M USD | 46.94M USD |
| Selling, general, and administrative | 24.11M USD | 25.68M USD | 29.59M USD | 32.43M USD | 37.23M USD |
| Operating expenses | 49.39M USD | 62.45M USD | 59.67M USD | 57.05M USD | 84.17M USD |
| Interest income | — | 3.9M USD | 4.9M USD | — | — |
| Depreciation and amortization | 273K USD | 613K USD | 568K USD | 1.38M USD | 237.08K USD |
| Operating income | −42.44M USD | −61.89M USD | −59.28M USD | −55.55M USD | 124.21M USD |
| Net income | −17.41M USD | −26.43M USD | −52.34M USD | −54.17M USD | 122.83M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.67
171.14% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI15.09M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM10.06M0.01%78.74B USD0.19%$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI6.58M0.07%9.87B USD0.35%$153.77+3.00%
Vanguard Extended Market ETFVXF5.28M0.01%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO2.35M0.01%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC1.22M0.09%1.32B USD0.60%$183+0.11%
Fidelity Enhanced Small Cap ETFFESM1.21M0.02%6.41B USD0.28%$45.46+0.46%
iShares Core S&P Total U.S. Stock Market ETFITOT803.46K0.00%98.09B USD0.03%$169.66+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMiShares Core S&P Total U.S. Stock Market ETFITOTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
